VandanaGupta(Gupta)AbramsonMD

Oncology • Nashville, TN

Breast Cancer, Hematologic Oncology

Professor, Medicine (Oncology), Vanderbilt University School of Medicine

Join to view full profile

Dr. Abramson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Abramson's full profile

Already have an account?

Office
3601 Pierce Ave
Nashville, TN 37232
Phone+1 615-936-2000

Fax+1 615-343-3212

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2003 - 2006
Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2003
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2000

Certifications & Licensure

TN State Medical License 2008 - 2025
TN State Medical License 2010 - 2025
TN State Medical License 2020 - 2025
AL State Medical License 2020 - 2020
PA State Medical License 2003 - 2008

Clinical Trials

Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer Start of enrollment: 2011 Feb 01
Withdrawn
Phase 2
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases Start of enrollment: 2011 Sep 01
Completed
Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Start of enrollment: 2013 May 01
Active, not recruiting
Phase 2
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer Start of enrollment: 2013 Sep 01
Terminated
Phase 1, Phase 2
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer Start of enrollment: 2014 Jan 30
Active, not recruiting
Phase 2
Cisplatin vs Paclitaxel for Triple Negative Breast Cancer Start of enrollment: 2014 Apr 01
Completed
Phase 2
Bioimpedance Spectroscopy Versus Tape Measure in Prevention of Lymphedema (PREVENT) Start of enrollment: 2014 Jun 01
Completed
Not Applicable
BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer Start of enrollment: 2015 Feb 01
Completed
Phase 1, Phase 2
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Start of enrollment: 2015 Jun 01
Terminated
Phase 1, Phase 2
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer Start of enrollment: 2016 Jan 28
Completed
Phase 2
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer Start of enrollment: 2016 Mar 01
Completed
Phase 1
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer Start of enrollment: 2021 Jan 11
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy Start of enrollment: 2023 Oct 02
Suspended
Phase 2
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
Withdrawn
Phase 1
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Start of enrollment: 2019 Jul 08
Recruiting
Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

476 citations
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff
The New England Journal of Medicine. 2019-02-20
195 citations
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond, Rebecca L. Moroose, Steven J. Isakoff
Journal of Clinical Oncology. 2017-03-14
209 citations
New strategies for triple-negative breast cancer--deciphering the heterogeneity
Ingrid A. Mayer, Vandana G. Abramson, Brian D. Lehmann, Jennifer A. Pietenpol
Clinical Cancer Research. 2014-02-15

Press Mentions

INAVO120 Trial Tests Inavolisib in HR+, HER2-, PIK3C-Alpha-Mutated DiseaseOctober 30th, 2024
FDA Expands Use of Breast Cancer Drug KisqaliSeptember 18th, 2024
FDA Expands Approval of Breast Most Cancers Drug Kisqali to Earlier Stage SufferersSeptember 17th, 2024
Join now to see all

Grant Support

Pet-Mri For Assessing Treatment Response In Breast Cancer Clinical TrialsNational Cancer Institute2010–2012
AKT Inhibitor Mk-2206 For Breast Cancers With A PIK3CA Mutation AND/OR PTEN LossNational Cancer Institute2011